Sanara MedTech (SMTI) Is Down 23.5% After Q3 Loss and THP Exit – Has the Investment Case Shifted?

• Sanara MedTech Inc. has reported its third quarter 2025 earnings, revealing sales of US$26.33 million and a net loss of US$30.41 million, and announced the discontinuation of its Tissue Health Plus (THP) operations completed in November 2025 as part of a business realignment toward its core surgical segment.
• This shift not only repositions the company’s operational focus but also signals a response to deeper losses and the challenges faced by its digital health initiative.
• Now, we'll explore how the THP discontinuation and increased net loss affect Sanara MedTech's investment narrative and future direction.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Sanara MedTech Investment Narrative Recap

To be a shareholder in Sanara MedTech right now, you need conviction in the company’s ability to unlock growth and margin expansion by focusing on surgical wound care, even as it steps back from digital health. The discontinuation of Tissue Health Plus (THP) may clarify short-term priorities, but the sharp increase in net loss is a reminder that persistent unprofitability remains the company’s biggest immediate hurdle, outweighing any positive near-term catalyst.

Among the recent developments, the completed wind-down of the THP segment is most relevant. With management now reallocating resources to the core surgical business, this move is significant because it directly addresses operating efficiency, yet it leaves the company’s revenue diversification and long-term SaaS ambitions uncertain, tempering optimism around short-term sales progress in its traditional wound care lines.

However, despite management signaling a new focus, investors should be aware that ongoing high net losses and limited profitability remain a material concern...

Read the full narrative on Sanara MedTech (it's free!)

Sanara MedTech's narrative projects $144.9 million revenue and $1.9 million earnings by 2028. This requires 14.2% yearly revenue growth and an $11.8 million increase in earnings from the current -$9.9 million.

Uncover how Sanara MedTech's forecasts yield a $50.00 fair value, a 137% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community members estimated fair values for Sanara MedTech between US$20.90 and US$50.00 per share. While shareholders see potential upside, continued large losses and uncertainty around digital health could constrain future gains and warrant consideration of differing outlooks.

Explore 3 other fair value estimates on Sanara MedTech - why the stock might be worth over 2x more than the current price!

Build Your Own Sanara MedTech Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Sanara MedTech research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Sanara MedTech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sanara MedTech's overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 37 companies in the world exploring or producing it. Find the list for free.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com